School of Medicine, and I'm Chief of the Division of Endocrinology at North Shore University Hospital in Manhasset, New York. I'm here today as an endocrinologist and thyroidologist, and being from New York, we require support, and as such, I serve as a consultant to King Pharmaceuticals.
For the past 20 years, I've been interested in the clinical and research aspects of thyroid disease, specifically the effects of thyroid hormone on the heart. I've published over a 150 articles on the subject, including chapters on thyroid hormone in the heart, in the Thyroid Textbook, and the chapter on cardiovascular endocrinology in the upcoming edition of Brownwald's Heart Disease.
The issue that I'd like to specifically address deals with the assessment of the therapeutic efficacy of different L-thyroxine sodium preparations when used in the treatment of hypothyroidism. As you're well aware, L‑thyroxine sodium is a narrow therapeutic index drug. After a diagnosis of hypothyroidism is established, treatment is initiated and the L-thyroxine replacement